(19)
(11)EP 4 219 566 A3

(12)EUROPEAN PATENT APPLICATION

(88)Date of publication A3:
06.09.2023 Bulletin 2023/36

(43)Date of publication A2:
02.08.2023 Bulletin 2023/31

(21)Application number: 23150323.6

(22)Date of filing:  23.12.2008
(51)International Patent Classification (IPC): 
C07K 19/00(2006.01)
A61K 39/155(2006.01)
A61K 9/107(2006.01)
A61P 31/14(2006.01)
C07K 14/135(2006.01)
C12N 15/62(2006.01)
A61K 39/12(2006.01)
A61K 39/00(2006.01)
A61K 39/295(2006.01)
A61K 9/127(2006.01)
A61P 37/04(2006.01)
C12N 15/45(2006.01)
C07K 14/005(2006.01)
(52)Cooperative Patent Classification (CPC):
A61K 39/155; A61K 2039/55572; A61K 2039/55577; C07K 14/005; C07K 16/1027; C07K 2317/21; C07K 2317/76; C07K 2319/73; C12N 2760/18522; C12N 2760/18534; A61K 2039/55505; A61K 39/12; A61P 31/00; A61P 31/12; A61P 31/14; A61P 37/00; A61P 37/04; Y02A 50/30
(84)Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

(30)Priority: 24.12.2007 US 1652407 P
27.05.2008 US 5620608 P

(62)Application number of the earlier application in accordance with Art. 76 EPC:
19152924.7 / 3508505
16180926.4 / 3109258
08864495.0 / 2222710

(71)Applicants:
  • ID Biomedical Corporation of Quebec
    Quebec G1P 4R8 (CA)
  • GlaxoSmithKline Biologicals S.A.
    1330 Rixensart (BE)

(72)Inventors:
  • BAUDOUX, Jean-Pierre
    1330 Rixensart (BE)
  • BLAIS, Normand
    Laval, H6V 3S8 (CA)
  • RHEAULT, Patrick
    Laval, H7V 3S8 (CA)
  • RUELLE, Jean-Loius
    1330 Rixensart (BE)

(74)Representative: J A Kemp LLP 
80 Turnmill Street
London EC1M 5QU
London EC1M 5QU (GB)

  


(54)RECOMBINANT RSV ANTIGENS


(57) This disclosure provides recombinant respiratory syncytial virus (RSV) antigens and methods for making and using them, including immunogenic compositions (e.g. vaccines) for the treatment and/or prevention of RSV infection.





Search report





















Search report